The existence of a small population of 'cancer-initiating cells' responsible for tumour maintenance has been firmly demonstrated in leukaemia. This concept is currently being tested in solid tumours. Leukaemia-initiating cells, particularly those that are in a quiescent state, are thought to be resistant to chemotherapy and targeted therapies, resulting in disease relapse. Chronic myeloid leukaemia is a paradigmatic haematopoietic stem cell disease in which the leukaemia-initiating-cell pool is not eradicated by current therapy, leading to disease relapse on drug discontinuation. Here we define the critical role of the promyelocytic leukaemia protein (PML) tumour suppressor in haematopoietic stem cell maintenance, and present a new therapeutic approach for targeting quiescent leukaemia-initiating cells and possibly cancer-initiating cells by pharmacological inhibition of PML.
The existence of cancer-initiating cells (CICs), a minor subpopulation of cells responsible for tumour initiation and maintenance, was proposed over 40 years ago 1 . In leukaemia in particular, increasing evidence suggests that out of the bulk of leukaemic cells only a rare population of leukaemia-initiating cells (LICs) propagates the disease [2] [3] [4] [5] [6] [7] . LICs are rare and share many properties of normal haematopoietic stem cells (HSCs), such as self-renewal, pluripotency and quiescence [4] [5] [6] . A fundamental problem in treating leukaemia lies in the fact that LICs remain untouched by both conventional chemotherapy and even by targeted therapies 7 . The quiescent LIC subpopulation is thought to be particularly resistant to drugs that would normally target cells in active DNA replication 7 . Hence leukaemia relapse may occur because therapies eliminate proliferating cells that constitute the bulk of the tumour, but fail to eradicate quiescent LICs that can reinitiate malignancy after a period of latency. Therefore, development of new therapeutic approaches targeting CICs and LICs may have a profound impact on cancer eradication.
Chronic myeloid leukaemia (CML) is one of the most extensively investigated and paradigmatic stem cell disorders 7 . It is characterized by the presence of the Philadelphia chromosome, which results from a chromosomal translocation between the BCR gene on chromosome 22 and the ABL gene on chromosome 9 (refs 8, 9) . This translocation generates the fusion protein BCR-ABL which displays constitutive kinase activity 10 . The tyrosine kinase inhibitor imatinib markedly improves the prognosis of CML patients 11, 12 ; however, imatinib preferentially targets dividing cells, whereas non-dividing leukaemic cells are resistant to imatinib-mediated apoptosis 6 . Surviving leukaemia stem and progenitor cells are a potential source for relapse. This is demonstrated by the fact that, if therapy is discontinued, the disease inevitably relapses in most cases, including those showing good responses without signs of disease progression [13] [14] [15] [16] [17] [18] . The PML gene, which is involved in the t(15;17) chromosomal translocation of acute promyelocytic leukaemia (APL), encodes a protein localizing to PML nuclear bodies, a subnuclear macromolecular structure 19 . PML functions as a tumour suppressor that controls fundamental processes such as apoptosis, cellular proliferation and senescence 20, 21 . Recent data demonstrated that PML is involved in neoangiogenesis and acts as a negative regulator of mTOR 22 . However, its role in stem cell biology has not been investigated. Here, we studied the role of PML in HSC and LIC biology and obtained unexpected data that have implications for the eradication of LICs and CICs in human cancer.
Loss of PML predicts favourable outcome in CML
To understand whether PML expression is modulated during haematopoiesis, we analysed Pml protein levels in various haematopoietic cell lineages in the mouse. To detect Pml levels in rare HSCs, we sorted different cell lineages directly into a sample buffer. Western blot analysis showed that Pml is highly expressed in the HSC compartment (Fig. 1a) . Immunofluorescence analysis also showed increased numbers of PML nuclear bodies in HSCs compared to committed cells ( Supplementary Fig. 1a ). Pml mRNA levels were also higher in the HSC population, indicating that Pml expression during haematopoiesis is regulated at the transcriptional level (Fig. 1b) . High PML expression in the HSC compartment was also observed in primary human bone marrow samples ( Supplementary Fig. 1b, c) .
We next evaluated PML expression in samples of patients with haematopoietic malignancies. Loss of PML is frequently observed in human cancers such as prostate and lung cancer 23, 24 . However, most CML chronic phase samples expressed high levels of PML (Fig. 1c) . Moreover, PML expression was barely detected in differentiated neutrophils whereas abundant PML expression was seen in blasts expressing CD34 (Fig. 1c and Supplementary Fig. 1d ). An unexpected association was found between PML positivity and clinical outcome: CML patients with low PML expression displayed higher complete molecular response (CMR) and complete cytogenetic response (CCyR) compared with patients with high PML expression (Fig. 1d, e) . Furthermore, low PML expression was strikingly predictive of better overall survival in CML ( Supplementary  Fig. 2 ). These results indicate that in CML, low PML expression predicts a better clinical outcome contrary to what was observed in prostate cancer and other solid tumours 23, 24 . These results prompted us to analyse the role of PML in haematopoiesis.
Pml is required for HSC maintenance Genetic loss of Pml did not induce significant changes in the number of haematopoietic cells in peripheral blood (data not shown) and in the quantity or quality of progenitors in the bone marrow in 8-weekold mice ( Supplementary Fig. 3a-d) . However, an increased number of cells in the c-Kit
Lin
-(KSL) stem cell compartment was found in 8-week-old Pml -/-mice (Fig. 2a) . In particular, the number of long-term repopulating HSCs measured as CD34 2 and Thy1 low KSL cells was significantly higher in 8-week-old Pml-deficient mice (Fig. 2a) . The proportion of cells in G0 among KSL and CD34 2 KSL cells, as evaluated by pyronin Y staining 25 , was markedly lower in Pml -/-mice than in wild-type mice (Fig. 2b) , indicating that Pml -/-HSCs are not quiescent. Consistent with these data, the number of colony-forming cells from Pml -/-KSL cells was higher than wild-type KSL cells after short-term culture on stromal cells (less than 2 weeks). However, the number of colonies from Pml -/-KSL cells decreased significantly after 6 weeks of culture (Fig. 2c) . These results suggest that increased cycling of Pml -/-HSCs results in their exhaustion. To assess the repopulating ability of Pml -/-HSCs in vivo, we performed a competitive reconstitution assay. Flow cytometric analysis revealed that Pml -/-KSL cells contributed to haematopoietic reconstitution more than competitor cells 4 weeks after transplantation (Fig. 2d) ; however, the percentage of Pml -/-KSL cells significantly decreased 16 weeks after transplantation (Fig. 2d) . These results indicate that Pml acts to maintain HSCs and that Pml -/-HSCs lack long-term repopulating capacity. This defect affected both myeloid as well as B and T lineages ( Supplementary Fig. 4a ). Cell cycle analysis of recipient bone marrow revealed that more HSCs from Pml -/-donors were cycling than those from wild-type donors (Fig. 2e) , indicating that Pml -/-HSCs are not quiescent in the bone marrow of recipient mice. Analysis of chimaerism revealed that all haematopoietic lineages from Pml -/-donors were affected, but the greatest reductions were seen in the HSC compartment (Fig. 2f) . In addition, the contribution of Pml -/-HSCs to more committed cells was more significantly impaired at later time points after transplantation ( Supplementary Fig. 4b ).
The impact of Pml deficiency on long-term repopulation was determined by carrying out a second competitive bone marrow transplantation (BMT). Pml -/-donor-derived cells could not reconstitute the bone marrow of recipient mice in the second BMT (Supplementary Fig. 4c ). Consistent with these data, defects in progenitor function were observed in Pml -/-donor-derived cells after BMT ( Supplementary Fig. 4d ). To assess HSC function under normal homeostatic conditions, we examined the effect of Pml deficiency on haematopoiesis in older mice. Older Pml -/-mice exhibited a progressive decrease in cellularity, with a mean ratio of bone marrow mononuclear cells compared to wild-type mice of 0.67 6 0.07 and 0.50 6 0.06 at 12 and 18 months. Additionally, in contrast to the increased number of KSL cells seen at 2 months of age, a significant reduction of HSCs was evident in Pml -/-bone marrow at 18 months (Fig. 2g) , accompanied by marked progenitor dysfunction ( Supplementary Fig. 4e ). Finally, repopulating cells from 18-month-old Pml -/-bone marrow were not detected in recipient mice even 4 weeks after transplantation ( Supplementary  Fig. 4f ). Thus, our data indicate that chronic Pml deficiency in vivo results in progressive impairment of HSC function due to defective maintenance of quiescence.
PML is indispensable for LIC maintenance
LICs have notable mechanistic similarities to normal stem cells 2, 4, 26 . Therefore, because high PML expression was seen in CML blasts (Fig. 1c) , we investigated the function of PML in CML LICs. Pml 1/1 and Pml -/-bone marrow cells were transduced with p210 BCR-ABL , and then cultured on stromal cells to enrich LICs. Pyronin Y staining of KSL cells revealed a significant reduction in the number of quiescent cells in Pml-deficient cells compared to wild-type cells (Fig. 3a) . Consistent with these data, Pml null LICs showed increased colony-forming capacity after short-term culture but remarkable reduction in colony number after long-term culture on stromal cells when compared with wild-type LICs (Fig. 3b) . To investigate the function of Pml in LICs in vivo, we serially transplanted bone marrow cells transduced with p210
BCR-ABL to recipient mice every 2 weeks. Retroviral transduction of p210 BCR-ABL results in transformation of bone marrow cells, resulting in CML-like disease 27 . In the first BMT, Pml -/-LICs promoted earlier CML-like disease in recipient mice than wild-type LICs ( Supplementary Fig. 5a, b) . When cell cycle status was investigated, significantly fewer Pml-deficient than wild-type LICs appeared in G0 in recipient mice (Fig. 3c) .
In the second BMT, no significant difference in survival was observed ( Supplementary Fig. 5c ). In the third serial BMT, however, Pml -/-LICs failed to generate CML-like disease, contrary to wild-type LICs (Fig. 3d-f and Supplementary Fig. 5d ). In addition, minimal residual disease was not detected in recipient mice transplanted with Pml -/-LICs (Fig. 3g) . Remarkably, wild-type LICs retained the potential to develop CML-like disease even in the fourth serial BMT ( Supplementary  Fig. 5e ). These results indicate that Pml-deficient LICs undergo intensive cell cycling, resulting in impairment of LIC maintenance.
As 2 O 3 reversibly decreases PML expression in HSCs
The inorganic arsenite arsenic trioxide (As 2 O 3 ) has been used as a therapeutic agent for centuries 28 . From the 1700s through to the early 1900s, arsenicals were a mainstay in the treatment of leukaemia 29 . The dramatic ability of arsenic to cure APL was reported in the mid1990s [30] [31] [32] . Arsenic has been shown to target PML for degradation 33 . Indeed, when we analysed the effect of As 2 O 3 treatment on mouse HSCs, we found that it reversibly decreased Pml expression in the HSC compartment in vitro (Fig. 4a) . Reduction of Pml expression by As 2 O 3 markedly attenuated colony-formation ability of wild-type KSL cells compared to control cells after 6 weeks on stromal cells, whereas an increase in colony formation was observed after shortterm culture (Fig. 4b) . Notably, As 2 O 3 treatment did not affect colony formation from Pml -/-HSCs (Fig. 4b) , indicating that this effect is mostly Pml-dependent. In vivo treatment with As 2 O 3 also reversibly reduced Pml expression ( Supplementary Fig. 6 ), and resulted in impaired HSC quiescence and an increase in the number of KSL cells (Fig. 4c, d) . Furthermore, the number of long-term repopulating HSCs was significantly more elevated after As 2 O 3 treatment (Fig. 4e) .
Rapamycin rescues the phenotype of Pml 2/2 HSCs and LICs
Recent data have demonstrated that PML acts as a repressor of neoangiogenesis by repressing mTOR activity in conditions of hypoxia 22 . Because mTOR has an essential role in HSC maintenance
Relative absolute number (KSL) Fig. 7a ). In vitro treatment with the mTOR inhibitor rapamycin substantially restored colony-forming capacity in long-term cultures of Pml -/-HSCs, whereas it did not affect wild-type HSCs (Supplementary Fig. 7b ).
In vivo administration of rapamycin increased the quiescence of Pml -/-HSCs ( Supplementary Fig. 7c ) and resulted in decreased numbers of Pml -/-long-term HSCs (Supplementary Fig. 7d ). Moreover, rapamycin treatment dramatically restored the capacity of Pml-deficient HSCs to provide long-term bone marrow reconstitution to irradiated mice ( Supplementary Fig. 7e, f) . These results indicate that Pml has an important role in the maintenance of HSCs by repressing mTOR activity.
We next examined the effect of rapamycin on Pml-deficient LICs. Administration of rapamycin significantly prevented the exhaustion of Pml -/-LICs, leading to restored colony-forming capacity in longterm culture (Supplementary Fig. 7g ). In addition, Pml -/-LICs treated with rapamycin gave rise to CML-like disease in the third serial BMT, although in the first BMT disease onset was delayed ( Supplementary Fig. 7 h-j) . Notably, rapamycin also accelerated CML-like disease by wild-type LICs in the third serial BMT (Supplementary Fig. 7i ). These results suggest that Pml acts as a repressor of mTOR activity in LICs and mTOR super-activation impairs LIC-maintenance.
PML downregulation is effective for LIC eradication
Interventions that enhance cycling of quiescent, chemotherapyinsensitive LICs are expected to facilitate their elimination.
Therefore we investigated the therapeutic effect of As 2 O 3 -mediated PML reduction in LICs. As 2 O 3 treatment significantly decreased the number of quiescent LICs without inducing apoptosis ( Fig. 5a and Supplementary Fig. 8 ). Consistently, long-term culture-initiating cell assays revealed a remarkable inhibitory effect of As 2 O 3 on LIC maintenance (Fig. 5b) .
To verify whether As 2 O 3 -induced cycling could increase the proapoptotic effect of chemotherapy on LICs, we combined arsenic and cytosine arabinoside (Ara-C) treatment. Arsenic followed by Ara-C exposure significantly increased the efficacy of Ara-C-mediated induction of apoptosis, resulting in eradication of LICs even 4 weeks after treatment discontinuation (Fig. 5c and Supplementary Fig. 9a) .
To analyse the effect of combination therapy on the persistence of long-term repopulating LICs, we treated LICs ex vivo, and next carried out serial transplantation assays. In the second round of BMT, mice transplanted with LICs treated with Ara-C succumbed around 20 days after BMT (Supplementary Fig. 9b ). However, when donor LICs were treated with As 2 O 3 and Ara-C, CML-like disease was not observed in recipient mice up to 40 days after BMT. These results indicate that induction of cell cycle entry by As 2 O 3 remarkably enhances the effect of Ara-C, leading to a significant increase in survival. Furthermore, we not only observed a marked survival advantage, but also a complete cure in more than half of recipient mice ( Supplementary Fig. 9b ). Notably, residual disease was not detected in these mice (Supplementary Table 1) .
Notably, we observed that there are fewer quiescent cells in p210 BCR-ABL expressing cells than in control KSL cells (Supplementary Fig. 10a, b) , indicating that the reservoir of quiescent cells is higher in HSCs than LICs. Moreover, exit from quiescence induced by As 2 O 3 treatment was significantly more profound in LICs than in HSCs (Supplementary Fig. 10c ). Similarly, a more profound reduction in LICs quiescence was observed in the Pml null setting (Supplementary Fig. 10d ). Taken together, these findings suggest that LICs are more sensitive to induction of cell cycle entry by As 2 O 3 than HSCs. Consequently, through induction of apoptosis, combination therapy with As 2 O 3 and Ara-C affected LIC function significantly more than normal HSC function in long-term culture assays ( Fig. 5d and Supplementary Fig. 10e ).
We next investigated the effect of combination therapy on LIC maintenance in a serial transplantation model. After BMT of cells transduced with p210 BCR-ABL or empty vector, in vivo administration of As 2 O 3 to recipient mice followed by Ara-C treatment induced remarkable apoptosis in LICs (Fig. 5e) . Transduced KSL cells were also much more prone to cell cycle entry by As 2 O 3 treatment than control KSL cells in the transplantation model ( Fig. 5f ) and significantly more apoptosis was observed in LICs treated with As 2 O 3 and Ara-C than in HSCs (Fig. 5g) .
Consequently, complete cure with no detectable residual disease was achieved in all recipient mice treated with combination therapy in the second and third round of BMT (Fig. 5h, Supplementary Fig.  11a , b and Supplementary Table 2 ). In the third BMT As 2 O 3 alone caused longer survival than Ara-C alone ( Supplementary Fig. 11b ), indicating that inhibition of maintenance may be more effective for tumour regression than targeting cycling cells with chemotherapy.
Finally, we analysed the impact of As 2 O 3 treatment on stem cells isolated from human CML patients. First, similarly to murine LICs, fewer quiescent cells were observed in LICs from CML patients compared to HSCs from healthy volunteers (Fig. 5i) . In addition, As 2 O 3 treatment induced cell cycle induction more remarkably in LICs than HSCs, and was accompanied by downregulation of PML (Fig. 5i, j and Supplementary Fig. 12a, b) . A more pronounced exit from quiescence in LICs compared to HSCs was also confirmed at the single cell level (Supplementary Fig. 12c ). Finally, in vitro pre-treatment of human CML LICs with As 2 O 3 followed by Ara-C induced significantly more apoptosis than Ara-C treatment alone, and a more profound apoptotic response was observed in LICs than in HSCs from healthy volunteers (Fig. 5k) .
Discussion
It has been suggested that a rare population of leukaemic cells with stem characteristics (LICs) sustains the development of at least some form of leukaemia, including CML 2 . These cells are unresponsive to therapy and have been suggested as a cause of disease relapse 6, 7, 36 . Therefore, therapeutic strategies that target LICs are necessary to eradicate residual disease and to prevent leukaemia relapse.
We used a CML mouse model to analyse LIC function in the absence of the tumour suppressor Pml and revealed that Pml has an indispensable role in maintaining LIC quiescence. Pml-deficient LICs become exhausted with time and are incapable of generating CML in transplanted animals. Hence we proposed that there could be a therapeutic window in targeting PML for therapy.
On the basis of this assumption, we used As 2 O 3 -a drug that downregulates PML expression by targeting it for degradation 33 and is currently used for the treatment of APL with very limited toxicity 30 -to mimic loss of Pml. Inhibition of Pml by As 2 O 3 disrupted LIC maintenance and increased the efficacy of anti-leukaemic therapy by sensitizing LICs to pro-apoptotic stimuli. Consistent with the notion that targeting the quiescent LICs might be an effective strategy to cure CML, administration of growth factors or bryostatin-1 was previously shown to reduce quiescent CML cells and residual disease after imatinib treatment ex vivo 6, 37 . Treatment with As 2 O 3 in CML might prove therapeutically beneficial because this agent is already in the clinic where it already proved to be extremely well tolerated in extensive preclinical trials in mouse models 33, 38, 39 and in human APL [30] [31] [32] . Finally, although loss of Pml and As 2 O 3 treatment also induce cycling of HSCs, Pml -/-HSCs are less affected than LICs and can sustain a normal lifespan in the mouse. On the basis of our findings, we therefore propose that As 2 O 3 or novel PML-lowering drugs should be used transiently at leukaemia onset, along with, or followed by, a standard of care regimens.
In previous studies, we showed that loss of Pml leads to an acceleration of APL in mouse models 40, 41 . These data are coherent with the initial acceleration of Pml-deficient CML reported in this work ( Supplementary Fig. 5a, b) . Although there is no clear evidence that APL originates from a HSC, future work will be important to establish if Pml deficiency or As 2 O 3 treatment leads to the exhaustion of the APL LIC in serial transplantation experiments. This is a plausible hypothesis coherent with the fact that PML-RAR-a may not inhibit PML function completely and that As 2 O 3 is extremely effective in the treatment of APL.
Our data demonstrate an unexpected and critical role for PML in stem cell biology and point at its therapeutic targeting as a promising avenue to eradicate LICs in leukaemia. It remains to be determined whether PML exerts a similar role in stem cells in other tissues and in CICs in other tumours, and if the transient use of As 2 O 3 may therefore represent a more global strategy to target the CIC in other forms of cancer.
METHODS SUMMARY
Mice. Generation of Pml-deficient mice (129Sv) has been described 42 . As 2 O 3 (2.5 mg per kg body weight per day) was administered by intraperitoneal injection as described 39 . Western blot. Each lineage compartment was flow-sorted directly into individual wells of a U-bottom 96-well plate containing 23 protein sample buffer. The lysate was briefly boiled and analysed by immunoblotting. The following antibodies were used: anti-b-actin (A-5316, Sigma), anti-mouse Pml (S36 and S37 monoclonal antibodies, provided by S. Lowe) and anti-human PML (Chemicon, rabbit polyclonal antibody) for human PML. Proteins were visualized using the SuperSignal western blotting kit (Pierce). Relative protein expression signals were normalized by comparison with b-actin signals. Bone-marrow infection and transplantation experiments. Bone-marrow infection and transplantation into lethally irradiated Ly45.1 congenic mice were performed as reported 43 . For serial transplantation, 2.5 3 10 6 bone marrow mononuclear cells were collected from recipient mice 2 weeks after BMT (first BMT) and transplanted into other recipient mice (second BMT). Subsequent transplantations were performed in the same manner. In some experiments, recipient mice were intraperitoneally injected with As 2 O 3 . Primary patient sample assay. Bone marrow samples from healthy volunteers and patients with chronic-phase CML before any therapy at diagnosis were obtained according to appropriate Human Protection Committee validation at the Keio University School of Medicine (Tokyo, Japan) and at the Beth Israel Deaconess Medical Center (Boston, Massachusetts, USA) with written informed consent. Cells were maintained in serum-free medium with a cytokine mixture containing 100 ng ml 21 of stem cell factor (SCF), 100 ng ml 21 of Flt-3 ligand (Peprotech) and 100 ng ml 21 of thrombopoietin (TPO) (Peprotech). To investigate division of HSCs and LICs, sorted Lin 
CD34
1 CD38 low/neg cells from healthy volunteers and CML patients were stained with CFSE (Molecular Probes). After 3 days of culture, fluorescence intensity of CFSE was analysed by FACS.
Full Methods and any associated references are available in the online version of the paper at www.nature.com/nature.
METHODS
Mice. Generation of Pml-deficient mice (129Sv) has been described 42 . C57BL/6 mice (B6-CD45.2) and C57BL/6 mice congenic for the CD45 locus (B6-CD45.1) were purchased from The Jackson Laboratory and crossed with 129Sv mice. F 3 B6/Sv129 mice were used as recipients in transplantation assays. As 2 O 3 (2.5 mg per kg body weight per day) was administered by intraperitoneal injection as described 39 . Long-term cultures and colony-forming assays. For long-term cultures, KSL cells were co-cultured with stromal cells in minimum essential media a modification (aMEM, Sigma) containing 12.5% FCS (JRH Bioscience), 12.5% horse serum (Gibco BRL) and 1.0 nM dexamethasone. After 2, 4 or 6 weeks of culture, cells were harvested and used for haematopoietic colony-forming assays as described 44 
